FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385431898> ?p ?o ?g. }

• W4385431898 endingPage "e18488" @default.
• W4385431898 startingPage "e18488" @default.
• W4385431898 abstract "Colorectal cancer (CRC) is the third most common cause of cancer-related morbidity worldwide, with an estimated of 1.85 million new cases and 850,000 deaths every year. Nevertheless, the current treatment regimens for CRC have many disadvantages, including toxicities and off-targeted side effects. STAT3 (signal transducer and activator of transcription 3) has been considered as a promising molecular target for CRC therapy. Brevilin A, a sesquiterpene lactone compound rich in Centipedae Herba has potent anticancer effects in nasopharyngeal, prostate and breast cancer cells by inhibiting the STAT3 signaling. However, the anti-CRC effect of brevilin A and the underlying mechanism of action have not been fully elucidated. In this study, we aimed to investigate the involvement of STAT3 signaling in the anti-CRC action of brevilin A. Here, HCT-116 and CT26 cell models were used to investigate the anti-CRC effects of brevilin A in vitro. HCT-116 cells overespressing with STAT3 were used to evaluate the involvement of STAT3 signaling in the anti-CRC effect of brevilin A. Screening of 49 phosphorylated tyrosine kinases in the HCT-116 cells after brevilin A treatment was performed by using the human phospho-receptor tyrosine kinase (phospho-RTK) array. Results showed that brevilin A inhibited cell proliferation and cell viability, induced apoptosis, reduced cell migration and invasion, inhibited angiogenesis, lowered the protein expression levels of phospho-Src (Tyr416), phospho-JAK2 (Y1007/1008) and phospho-STAT3 (Tyr705), and inhibited STAT3 activation and nuclear localization. Brevilin A also significantly reduced the protein expression levels of STAT3 target genes, such as MMP-2, VEGF and Bcl-xL. More importantly, over-activation of STAT3 diminished brevilin A's effects on cell viability. All these results suggest that brevilin A exerts potent anti-CRC effects, at least in part, by inhibiting STAT3 signaling. Our findings provide a strong pharmacological basis for the future exploration and development of brevilin A as a novel STAT3-targeting phytotherapeutic agent for CRC treatment." @default.
• W4385431898 created "2023-08-01" @default.
• W4385431898 creator A5007592619 @default.
• W4385431898 creator A5007944172 @default.
• W4385431898 creator A5011090841 @default.
• W4385431898 creator A5017582956 @default.
• W4385431898 creator A5017760691 @default.
• W4385431898 creator A5062891932 @default.
• W4385431898 date "2023-08-01" @default.
• W4385431898 modified "2023-10-16" @default.
• W4385431898 title "Brevilin A exerts anti-colorectal cancer effects and potently inhibits STAT3 signaling in vitro" @default.
• W4385431898 cites W1993019389 @default.
• W4385431898 cites W2009062406 @default.
• W4385431898 cites W2016091072 @default.
• W4385431898 cites W2061050600 @default.
• W4385431898 cites W2113231588 @default.
• W4385431898 cites W2134061119 @default.
• W4385431898 cites W2255650872 @default.
• W4385431898 cites W2281343367 @default.
• W4385431898 cites W2330829715 @default.
• W4385431898 cites W2778868519 @default.
• W4385431898 cites W2794594588 @default.
• W4385431898 cites W2896909268 @default.
• W4385431898 cites W2913406096 @default.
• W4385431898 cites W2917410143 @default.
• W4385431898 cites W2920863623 @default.
• W4385431898 cites W2925322596 @default.
• W4385431898 cites W2928431398 @default.
• W4385431898 cites W2946250323 @default.
• W4385431898 cites W2952931735 @default.
• W4385431898 cites W2965651111 @default.
• W4385431898 cites W2971430969 @default.
• W4385431898 cites W2982116988 @default.
• W4385431898 cites W2983881420 @default.
• W4385431898 cites W2985106473 @default.
• W4385431898 cites W2987812036 @default.
• W4385431898 cites W2995873552 @default.
• W4385431898 cites W2999308880 @default.
• W4385431898 cites W3011481749 @default.
• W4385431898 cites W3014744250 @default.
• W4385431898 cites W3015412873 @default.
• W4385431898 cites W3017207618 @default.
• W4385431898 cites W3035181787 @default.
• W4385431898 cites W3035225879 @default.
• W4385431898 cites W3041172063 @default.
• W4385431898 cites W3087664139 @default.
• W4385431898 cites W3093514124 @default.
• W4385431898 cites W3112676092 @default.
• W4385431898 cites W3115858881 @default.
• W4385431898 cites W3120689400 @default.
• W4385431898 cites W3128646645 @default.
• W4385431898 cites W3147475204 @default.
• W4385431898 cites W3153389700 @default.
• W4385431898 cites W3154196314 @default.
• W4385431898 cites W3154826816 @default.
• W4385431898 cites W3175064583 @default.
• W4385431898 cites W3189155982 @default.
• W4385431898 cites W335253295 @default.
• W4385431898 cites W4210276541 @default.
• W4385431898 cites W4210480653 @default.
• W4385431898 cites W4213456241 @default.
• W4385431898 cites W4220666987 @default.
• W4385431898 cites W4283374859 @default.
• W4385431898 doi "https://doi.org/10.1016/j.heliyon.2023.e18488" @default.
• W4385431898 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37593607" @default.
• W4385431898 hasPublicationYear "2023" @default.
• W4385431898 type Work @default.
• W4385431898 citedByCount "0" @default.
• W4385431898 crossrefType "journal-article" @default.
• W4385431898 hasAuthorship W4385431898A5007592619 @default.
• W4385431898 hasAuthorship W4385431898A5007944172 @default.
• W4385431898 hasAuthorship W4385431898A5011090841 @default.
• W4385431898 hasAuthorship W4385431898A5017582956 @default.
• W4385431898 hasAuthorship W4385431898A5017760691 @default.
• W4385431898 hasAuthorship W4385431898A5062891932 @default.
• W4385431898 hasBestOaLocation W43854318981 @default.
• W4385431898 hasConcept C121608353 @default.
• W4385431898 hasConcept C126322002 @default.
• W4385431898 hasConcept C171958077 @default.
• W4385431898 hasConcept C190283241 @default.
• W4385431898 hasConcept C2778923194 @default.
• W4385431898 hasConcept C502942594 @default.
• W4385431898 hasConcept C526805850 @default.
• W4385431898 hasConcept C55493867 @default.
• W4385431898 hasConcept C62112901 @default.
• W4385431898 hasConcept C62478195 @default.
• W4385431898 hasConcept C71924100 @default.
• W4385431898 hasConcept C86803240 @default.
• W4385431898 hasConcept C95444343 @default.
• W4385431898 hasConcept C98274493 @default.
• W4385431898 hasConceptScore W4385431898C121608353 @default.
• W4385431898 hasConceptScore W4385431898C126322002 @default.
• W4385431898 hasConceptScore W4385431898C171958077 @default.
• W4385431898 hasConceptScore W4385431898C190283241 @default.
• W4385431898 hasConceptScore W4385431898C2778923194 @default.
• W4385431898 hasConceptScore W4385431898C502942594 @default.
• W4385431898 hasConceptScore W4385431898C526805850 @default.
• W4385431898 hasConceptScore W4385431898C55493867 @default.

• next